Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

224
S&P 500: It's All In The Numbers And The Numbers Never Lie

2018-08-12 seekingalpha
We all talk much about FAANG and/or the tech sector. However, the market is far greater and more interesting than that.
SYMC XOM CVS WMT NWL AMZN CAH TSN BAC CHLKF AAL INCY 0941 BRK.A BHF CHL GOOGL JNJ MSFT MHK WFCNP FB ALB MCK NLSN LB BAC TSNU AAPL GM MCD WFC COST ABC V XRAY CVX UNH IVZ COTY

10
Your Daily Pharma Scoop: Insmed's AdCom, Opko Progresses, Roche PRIMEd

2018-08-06 seekingalpha
Insmed up 7% premarket ahead of Ad Com review of inhalable amikacin for NTM lung disease
ACOR ABC OPK HIK INSM ENL SLXP ENDP

13
UPDATE 1-U.S. subpoenas AmerisourceBergen over opioid products

2018-08-02 reuters
Aug 2 (Reuters) - Drug wholesale distributor AmerisourceBergen Corp said on Thursday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to opioid products and its communications with a drugmaker.
ABC MCK CAH ENL ENDP

3
U.S. subpoenas AmerisourceBergen over opioid products

2018-08-02 reuters
(Reuters) - Drug wholesale distributor AmerisourceBergen Corp said on Thursday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to opioid products and its communications with a drugmaker.
ABC

3
ABC / AmerisourceBergen Corp. 10-Q (Quarterly Report)

2018-08-02 sec.gov
Document Table of Contents
ABC

44
Meet The 'Safer' 35 Healthcare High Yield WallStars For July

2018-08-02 seekingalpha
McKesson took July's net gain "safer" Healthcare WallStar High Yield plaudits. Its projected 22.99% net gain was 10% better than AbbVie's, and 15% more than AmerisourceBergen's result per analyst targets.
ABT AMGN GRFS GILD A MCK ANTM ABT SNY ABC JNJ NVS ABBV PFE ABBV

8
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More

2018-08-01 zacks
The second-quarter earnings season is in full swing, with 265 members of the S&P 500 index having reported their financial numbers till Jul 27.
RMD ABC CERN SYK CACC RSMDF RMD ISRG

48
Cardinal Health: Too Cheap To Pass Up

2018-07-30 seekingalpha
The stock trades at roughly the same price as in 2013 which has piqued my interest.
ABC AMZN MCK CAH MDT

69
Applying A Low P/E Strategy Today

2018-07-30 seekingalpha
Applying low P/E strategy today: McKesson as a contrarian pick and YY as a GARP pick.
FB ABC AMZN HUYA GOOGL MCK AAPL MOMO CAH GOOG

44
Cryoport: Elucidating The Latest Developments Centering A CAR-T Servicer

2018-07-29 seekingalpha
Cryoport is a promising company approaching its growth inflection. Despite that it procured substantial profits for Integrated BioSci Investing, there are further upsides to this thesis.
ABC AMZN GILD CYRX NVS KITE

7
Cerner Corp. Will Continue To Thrive

2018-07-27 seekingalpha
I have been looking for ways to get exposure to the healthcare industry without owning any drug companies. There have been a few ideas worth researching over the past few months - take the distribution/supply chain companies within the industry, such as AmerisourceBergen (NYSE:ABC) comes to mind. Today, I present one of my favorite ideas for exposure.
ABC CERN AAPL

48
McKesson Vs. Cardinal Health: I Follow The Leader, And So Should You

2018-07-25 seekingalpha
Investors should not be fooled by the dividend yield: McKesson is a better choice over Cardinal.
ABC AMZN MCK CAH

32
Pharma's middlemen see shares suffer as challenges grow

2018-07-25 reuters
NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.
PFZ ABC MCK WBA CAH CI CVS 500680 PFE PFIZER

29
One Man’s $50 Billion Vendetta Against Opioids - Bloomberg

2018-07-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ABC TEVJF MCK TEVA TEVVF CAH ENL ENDP

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 03073E105